Sarizotan HC1 in Patients With Parkinson's Disease Suffering From Treatment-associated Dyskinesia
Sarizotan HC1 in Patients With Parkinson's Disease Suffering From Treatment-associated Dyskinesia
The purpose of this study is to determine if Sarizotan HC1 1 mg b.i.d. (taken twice a day) is
 effective in the treatment of dyskinesia associated with dopaminergic treatment of
 Parkinson's disease (PD).
Inclusion Criteria:

 -  The subject is an out-patient.

 -  The subject presents with a diagnosis of idiopathic Parkinson's disease.

 -  Prior therapy with all registered Parkinsonian medication is allowed.

 Exclusion Criteria:

 -  (For female subjects) The subject is pregnant or lactating.

 -  The subject is participating in another clinical study or has done so within the past
 30 days.

 -  The subject has received neurosurgical intervention related to PD.

 -  The subject has relevant renal impairment.

 -  The subject has relevant hepatic impairment.

 -  The subject is suffering from any dementia or psychiatric illness.

 -  The subject has a history of allergic asthma.